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Background: Patients with schizophrenia frequently switch between antipsychotics, underscoring the need to
achieve and maintain important treatment outcomes such as health-related quality of life (HRQoL) following the
switch. This analysis evaluated HRQoL changes among patients with schizophrenia switched from their current
antipsychotic to lurasidone.
Methods: Stable but symptomatic outpatients with schizophrenia were switched from their current antipsychotic
to lurasidone in a six-week, open-label trial. HRQoL was assessed using two validated patient-reported measures,
the Personal Evaluation of Transitions in Treatment (PETiT) scale and the Short-Form 12 (SF-12). Total and domain
scores (psychosocial function and adherence-related attitude) were assessed using the PETiT scale; patients’ mental
and physical component summary scores (MCS and PCS) were assessed using the SF-12. Changes in HRQoL from
baseline to study endpoint were compared using ANCOVA, with baseline score, treatment, and pooled site as
covariates. Changes were assessed among all patients and those switched from specific antipsychotics to lurasidone.
Results: The analysis included 235 patients with data on the PETiT and SF-12 who had received ≥1 dose of lurasi-
done. Statistically significant improvements were observed from baseline to study endpoint on the PETiT total
(mean change [SD]: 3.2 [8.5]) and psychosocial functioning (2.5 [6.9]) and adherence-related attitude (0.7 [2.6])
domain scores (all p ≤ 0.002). When examined by preswitch antipsychotic, significant improvements in PETiT total
scores were observed in patients switched from quetiapine, risperidone, aripiprazole, and ziprasidone (all p < 0.03)
but not olanzapine (p = 0.893). Improvements on the SF-12 MCS score were observed for all patients (mean change
[SD]: 3.7 [11.5], p < 0.001) and for those switched from quetiapine or aripiprazole (both p < 0.03). The SF-12 PCS scores
remained comparable to those at baseline in all patient groups.
Conclusions: These findings indicate that patients switching from other antipsychotics to lurasidone experienced
statistically significant improvement of HRQoL, based on PETiT scores, within six weeks of treatment. Patient health
status remained stable with respect to the SF-12 physical component and showed improvement on the mental
component. Changes in HRQoL varied based on the antipsychotic used before switching to lurasidone.
Trial registration: NCT01143077.
Keywords: Health-related quality of life, Lurasidone, Antipsychotic, PETiT, SF-12* Correspondence: gawad@hrrh.on.ca
1Department of Psychiatry, University of Toronto, Toronto, ON, Canada
2Department of Psychiatry and Mental Health, Humber River Regional
Hospital, Toronto, ON, Canada
Full list of author information is available at the end of the article
© 2014 Awad et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Awad et al. BMC Psychiatry 2014, 14:53 Page 2 of 10
http://www.biomedcentral.com/1471-244X/14/53Background
Schizophrenia is a severe, chronic, and costly psychiatric
disorder characterized by acute psychotic episodes. Af-
fected individuals demonstrate a heterogeneous pheno-
type that includes a vast array of symptomology, variable
responses to treatment, and poor health-related quality
of life (HRQoL) [1-4]. Patients with schizophrenia can
suffer from: (1) positive symptoms such as delusions,
hallucinations, conceptual disorganization, suspicious-
ness, agitation, and hostility; and (2) negative symptoms
such as blunted affect, emotional and social withdrawal,
lack of spontaneity, and poverty of speech [5]. These dis-
turbances have a pervasive impact on many areas of
patient functioning and frequently reduce HRQoL. The
cognitive deficits demonstrated by patients in the do-
mains of executive function, attention, memory, and lan-
guage are additionally recognized to negatively impact
functional outcomes such as psychosocial functioning,
work/education, and independent living [6-8]. Patient
HRQoL may also be impacted directly by the treatments
that are used to manage schizophrenia [9]. That is, while
antipsychotic medications are likely to have a positive
effect on patient well-being due to symptom improve-
ments, differences in side effects among currently avail-
able therapies (e.g., rates of hyperprolactinemia, weight
gain) may negatively impact functional status and overall
HRQoL. The different drugs in the atypical antipsychotic
class have varying pharmacological profiles, with differ-
ential impacts on the clinical response and adverse
effects among patients; therefore, they can have a differ-
ential impact on HRQoL [10,11].
Patient adherence to treatment has also been consider-
ably variable among different antipsychotics, and a pa-
tient’s subjective response or attitude to a therapy (i.e.,
how they perceive their clinical response and/or adverse
effects) may impact adherence [12]. Since tolerability
issues are common in the treatment of schizophrenia,
patients often discontinue therapy or switch between dif-
ferent types of antipsychotic medications in an effort to
find an optimal therapeutic regimen [13,14]. Moreover,
patients with schizophrenia are often only partially ad-
herent with their prescribed medications [15-17]. In a
systematic review of 39 studies that assessed adherence
using a variety of methods, approximately 40% of pa-
tients with the disorder were partially- or non-adherent
to antipsychotic therapies [17]. While the specific cause
is somewhat unclear, adherence-related attitude may
play a role in poor adherence, potentially being associ-
ated with patient perceptions of medication efficacy and
adverse effects [18-20].
Several studies have shown that poor adherence and/
or treatment discontinuation are associated with an in-
creased risk of relapse and re-hospitalization, both of
which may negatively affect HRQoL [21-23]. Thus, highdiscontinuation and switching rates between antipsy-
chotics underscores the need to ensure that important
outcomes of treatment—such as enhanced adherence
rates and improvements in HRQoL—are achieved and
maintained following the switch to another antipsychotic.
Lurasidone is a second-generation atypical antipsychotic
that received approval in October 2010 by the United
States (US) Food and Drug administration (FDA) for
the treatment of adult patients with schizophrenia [24].
Lurasidone can be differentiated from other available
second-generation atypical antipsychotics by its receptor
binding profile, with moderate affinities for the serotonin
5-HT7, noradrenaline α2c (antagonist), and serotonin
5-HT1A (weak-moderate partial agonist), in addition to
the expected high affinity binding for dopamine D2 and
serotonin 5-HT2A receptors. Lurasidone has little to no
appreciable affinity for the 5-HT2C, histamine H1, and
acetylcholine M1 receptors.
The results of a recently published study demonstrated
that switching clinically stable yet symptomatic patients
with schizophrenia or schizoaffective disorder to lurasi-
done from other antipsychotic agents was well tolerated,
with low rates of patient discontinuation [25]. This ana-
lysis aimed to assess changes in HRQoL in patients with
schizophrenia who were switched to lurasidone from
other antipsychotic agents in a six-week open-label mul-
ticenter parallel group trial using the Personal Evaluation
of Transitions in Treatment (PETiT) scale. In addition
to overall HRQoL, the study evaluated changes in sev-
eral important domains of HRQoL in schizophrenia
(adherence-related attitude, psychosocial functioning, so-
cial functioning, activity, patient perception of cognition,
and dysphoria) as measured by PETiT domain scores. The
secondary objective of the analysis included an assessment
of general health status in patients switching to lurasidone
using the Short-Form 12 (SF-12).
Methods
Core study design
The analysis was based on data from a six-week, open-
label, parallel-group trial of stable but symptomatic out-
patients with schizophrenia who were switched from
their current antipsychotic to lurasidone [25]. The de-
tailed methodology of this study has been reported
previously [25]. Briefly, the study was conducted at 28
sites in the United States (ClinicalTrials.gov identifier:
NCT01143077). The study protocol was reviewed and
approved by an institutional review board at each study
center, and the trial was conducted in accordance with
Good Clinical Practice as required by the International
Conference on Harmonization guidelines. Compliance
with these requirements also constitutes conformity with
the ethical principles of the Declaration of Helsinki. Sub-
jects had to provide informed consent to participate in
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stable, Diagnostic and Statistical Manual of Mental Dis-
orders IV (DSM-IV)–defined schizophrenia or schizoa-
ffective disorder who were considered appropriate
candidates for switching from their current antipsychotic
medications (due to insufficient efficacy and/or safety or
tolerability concerns). Subjects were randomized to one
of three lurasidone dosing regimens for the initial two
weeks of the study: (1) 40 mg/d for two weeks; (2)
40 mg/d for one week, then increased to 80 mg/d for
week two; and (3) 80 mg/d for two weeks. Over the ini-
tial two week course, the preswitch antipsychotic was ta-
pered to 50% at the first week visit and discontinued
totally at the second week visit. Lurasidone was then
flexibly dosed (40–120 mg/d) for the subsequent four
weeks. Patients randomized to all three dosing regimens
of lurasidone were pooled together for the study ana-
lysis. The core clinical trial categorized subjects switched
from olanzapine or quetiapine into the sedating anti-
psychotic group and patients switched from risperidone,
aripiprazole, or ziprasidone into the non-sedating
antipsychotic group a priori to the study [25]. This
categorization was an assumption based on literature
suggesting that olanzapine and quetiapine have greater
sedating characteristics than risperidone, aripiprazole,
and ziprasidone [26,27].
The primary study outcome was time to treatment
failure, defined as any occurrence of insufficient clinical
response, exacerbation of underlying disease, or discon-
tinuation due to an adverse event (AE), as determined
by investigator judgement. HRQoL and general health
status, including evaluation of physical functioning and
mental health, were studied as secondary endpoints
using the PETiT and SF-12 Patient Reported Outcomes
measures. The PETiT and SF-12 assessments were ad-
ministered at baseline and at six weeks.
Outcome measures
(i) PETiT Scale
The PETiT scale is a validated, 30-item instrument de-
signed to capture and quantify the impact of treatment
on self-perceived subjective aspects of patient HRQoL
[28]. The scale is known to assess two relevant domains: 1)
adherence-related attitude (six items, including adherence
and feelings towards medication) and psychosocial func-
tioning (24 items, including clarity, energy, concentration,
functioning, sex drive, and memory). Psychosocial func-
tioning was further assessed in terms of four sub-domains:
social functioning (four items on trust, confidence, and
interactions), activity (seven items on energy, ability to con-
duct daily tasks), cognitive (seven items on clarity, concen-
tration, and communication), and dysphoria (six items on
happiness, future, and self-esteem). Each item of the PETiT
scale is assigned a rating of 0, 1, or 2, where 0 denotes anegative change (i.e., worse HRQoL) and 2 denotes a posi-
tive change (i.e., better HRQoL). Total PETiT scale score
ranges from 0 to 60, with higher scores on PETiT denoting
better HRQoL.
(ii) SF-12
Quality of life outcomes were also assessed in patients
switched to lurasidone using the SF-12 survey, a multi-
purpose generic measure of health status [29]. The
SF-12 yields scale scores for items such as physical func-
tioning, role limitations, health perceptions, bodily pain,
vitality, social functioning, and mental health on the
basis of patient responses to 12 questions. The survey
yields two summary measures of physical and mental
health: the Physical Component Summary (PCS) and the
Mental Component Summary (MCS).
Analysis
The intent-to-treat (ITT) population was used for the
PETiT and SF-12 analysis. The ITT population was de-
fined as all patients who had received at least one dose
of lurasidone and had non-missing values for PETiT and
SF-12 scores at baseline and ≥1 post-baseline value at
study endpoint. The study endpoint was the last obser-
vation carried forward (LOCF), defined as the last
non-missing value for any PETiT or SF-12 item at a
scheduled or unscheduled visit post-baseline. Mean
changes from baseline to LOCF in PETiT and SF-12
scores were calculated using analysis of covariance
(ANCOVA) models, with treatment and pooled center
as fixed factors and baseline value as a covariate.
Mean changes from baseline to LOCF for the PETiT
scale total score, its domains, and the SF-12 PCS and
MCS scores were determined for all patients in the ITT
population. The analysis further examined PETiT and
SF-12 scores by the individual preswitch antipsychotic
medications that were received by ≥10% of patients in
the study. Scores were additionally examined by categor-
izing these medications into the sedating (olanzapine
and quetiapine) and non-sedating (risperidone, aripipra-
zole, and ziprasidone) subgroups. Finally, the analysis
also examined HRQoL among patients who had com-
pleted or discontinued treatment with lurasidone due to
any cause at study endpoint.
Results
Patient demographics & baseline characteristics
The study population was comprised of 240 patients with
schizophrenia or schizoaffective disorder who received at
least one dose of study medication. Table 1 presents the
baseline clinical characteristics for the total study popula-
tion. Of the 240 patients switched to lurasidone from
other antipsychotics, 235 patients with available data on
the PETiT scale and SF-12 assessment comprised the ITT
Table 1 Patient demographics and baseline clinical
characteristics
Parameter No. of subjects (%)*
N 240
Mean age






Black or African American 151 (62.9%)
Native Hawaiian or other Pacific Islander 1 (0.4%)
White 80 (33.3%)
Other 7 (2.9%)
DSM-IV Schizophrenia subtype diagnosis
295.10 Disorganized type 4 (1.7%)
295.20 Catatonic type 0
295.30 Paranoid type 125 (52.1%)
295.60 Residual type 2 (0.8%)
295.70 Schizoaffective disorder 89 (37.1%)
295.90 Undifferentiated type 21 (8.8%)









First-generation antipsychotic 17 (7.1%)
Treatment with concomitant lithium,
valproate or lamotrigine
34 (16.2%)
Treatment with concomitant antidepressant 104 (43.3%)
Mean age (SD) at initial onset of schizophrenia
or schizoaffective disorder, years
25.1 (9.3)
Mean positive and negative syndrome
scale total score (SD)
68.9 (13.8)
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tients were male (65%) and the mean age at study entry
was 43.9 years. For the purpose of this study, 152 of 235
patients (65%) were treated with a preswitch non-sedating
antipsychotic (risperidone, aripiprazole, ziprasidone) and83 of 235 (35%) were treated with a preswitch sedating
medication (olanzapine or quetiapine).
PETiT assessment
The mean (± standard deviation [SD]) PETiT total score
for all lurasidone patients improved from 35.0 (8.8) at
baseline to 38.5 (9.2) at LOCF endpoint, representing a
mean improvement of 3.2 (8.5) or 9.1% (p < 0.001). Im-
provements from baseline to LOCF endpoint in the total
score, as well as in the domains of adherence-related at-
titude (0.7 [2.6]) and psychosocial functioning (2.5 [6.9]),
were statistically significant (p ≤ 0.002) for all patients
who were switched to lurasidone (Table 2). All aspects
of the psychosocial functioning domain (activity, cogni-
tive, and dysphoria) showed significant improvement
(p ≤ 0.002) with the exception of social functioning,
where a non-significant improvement was demonstrated.
PETiT scores by preswitch antipsychotic medication
The differences in patients’ PETiT scores were also
stratified based on the antipsychotic medication used
prior to switching to lurasidone. To ensure a reasonable
sample size for this analysis, preswitch antipsychotic
medications received by ≥10% of patients in the study
were included for stratification. The medications in-
cluded quetiapine (n = 62), risperidone (n = 51), aripipra-
zole (n = 44), ziprasidone (n = 27), and olanzapine
(n = 24). Patients on all of these preswitch medications
except olanzapine showed statistically significant im-
provements in total PETiT scores, as determined by
mean changes from baseline to LOCF (±SD): quetiapine
4.2 (7.7), p = 0.011; risperidone 3.6 (7.9), p = 0.029; ari-
piprazole 3.4 (8.0), p = 0.010; ziprasidone 5.4 (7.9),
p = 0.009 (Table 3). Patients on these four agents also
showed significant improvements on the psychosocial
functioning component (all p < 0.05) (Table 3). For pa-
tients switched from olanzapine, a numerical decrease in
the total PETiT score and its components was observed;
however, this difference was not statistically significant.
Patients in the aripiprazole and ziprasidone preswitch
groups additionally showed statistically significant im-
provements in the adherence-related attitude compo-
nent (both p < 0.05).
PETiT scores by patients switched from sedating and
non-sedating antipsychotics
Differences in PETiT scores were also found between pa-
tients who had received a non-sedating antipsychotic
(risperidone, aripiprazole, ziprasidone) and those who
had received a sedating antipsychotic (olanzapine or
quetiapine) prior to the switch to lurasidone. In the
non-sedating group, statistically significant (p < 0.001)
improvements from baseline to LOCF endpoint were
observed for the total PETiT score and its psychosocial
Table 2 Mean change in PETiT assessments among patients switched to lurasidone
Parameter All patients* Sedating Non-sedating
(N = 235) (n = 83) (n = 152)
PETiT total score Baseline (SD) 35.0 (8.8) 33.8 (8.6) 35.7 (8.9)
LOCF (SD) 38.5 (9.2) 36.5 (10.1) 39.6 (8.5)
Mean change (SD) 3.2 (8.5) 2.7 (9.3) 3.5 (8.1)
p-value < 0.001 0.101 < 0.001
Adherence-related attitude domain score (6 items) Baseline (SD) 8.7 (2.1) 8.4 (2.0) 8.8 (2.1)
LOCF (SD) 9.4 (2.2) 8.9 (2.6) 9.7 (2.0)
Mean change (SD) 0.7 (2.6) 0.5 (2.8) 0.8 (2.4)
p-value 0.002 0.735 < 0.001
Psychosocial functioning domain score (24 items) Baseline (SD) 26.4 (7.7) 25.4 (7.6) 26.9 (7.8)
LOCF (SD) 29.1 (7.9) 27.7 (8.6) 29.9 (7.4)
Mean change (SD) 2.5 (6.9) 2.1 (7.4) 2.7 (6.6)
p-value < 0.001 0.074 < 0.001
Social functioning (4 items) Baseline (SD) 3.9 (1.4) 3.6 (1.4) 4.0 (1.4)
LOCF (SD) 4.0 (1.5) 3.6 (1.5) 4.2 (1.5)
Mean change (SD) 0.1 (1.4) −0.1 (1.5) 0.1 (1.4)
p-value 0.959 0.066 0.198
Activity (7 items) Baseline (SD) 7.7 (2.8) 7.6 (2.8) 7.8 (2.8)
LOCF (SD) 8.5 (2.9) 8.3 (3.0) 8.6 (2.9)
Mean change (SD) 0.7 (2.7) 0.6 (2.8) 0.8 (2.7)
p-value 0.002 0.124 0.002
Cognitive (7 items) Baseline (SD) 8.1 (2.8) 7.8 (2.7) 8.3 (2.8)
LOCF (SD) 9.1 (2.6) 8.8 (2.9) 9.3 (2.5)
Mean change (SD) 0.9 (2.5) 0.9 (2.8) 0.9 (2.4)
p-value < 0.001 0.006 < 0.001
Dysphoria (6 items) Baseline (SD) 6.7 (2.5) 6.4 (2.3) 6.8 (2.6)
LOCF (SD) 7.5 (2.4) 7.0 (2.7) 7.8 (2.1)
Mean change (SD) 0.8 (2.3) 0.7 (2.4) 0.9 (2.2)
p-value < 0.001 0.149 < 0.001
*Patients eligible for evaluation in the analysis (N = 235) may have non-missing values at baseline and ≥1 post-baseline value at study endpoint (LOCF) for any
PETiT items; n values may not sum to 235 due to missing data.
Note: preswitch sedating medications include quetiapine and olanzapine; preswitch non-sedating medications include risperidone, aripiprazole, and ziprasidone.
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(Table 2). While numerical improvements in the scores
for these three outcomes were observed in the sedating
group, these changes were not statistically significant.
PETiT scores by study discontinuation status
Patients were categorized as subjects who discontinued
(37 [16%]) or subjects who completed (198 [84%]) with
lurasidone in the ITT population based on discontinu-
ation due to any cause at the six-week endpoint. When
analyzed by discontinuation status, the study showed
that patients who completed treatment with lurasidone
had significantly improved PETiT total scores versus pa-
tients who discontinued treatment (p < 0.001) (Table 4).
This improvement was also observed in the adherence-related attitude and psychosocial functioning domains of
the PETiT scale (both p < 0.001).
SF-12 assessment
For all patients, the results of the SF-12 revealed that
health status remained stable following the switch to lur-
asidone, with small improvements observed for both the
PCS and MCS scores (Table 5). Improvements on the
MCS score were noted in all subgroups (all patients,
sedating, and non-sedating groups) following the switch
to lurasidone, with statistically significant differences
observed in the all patients (mean [SD]: 3.7 [11.5],
p < 0.001) and non-sedating (3.7 [10.4], p < 0.001) subgroups.
Overall, analysis of patients by preswitch antipsychotic
agent revealed little difference between baseline and LOCF
Table 3 Mean change in PETiT assessments by preswitch medication among patients switched to lurasidone (N = 235)*
Parameter Quetiapine Olanzapine Risperidone Aripiprazole Ziprasidone
(n = 62) (n = 24) (n = 51) (n = 44) (n = 27)
PETiT total score Baseline (SD) 31.6 (7.8) 39.1 (9.9) 38.3 (8.7) 35.1 (6.9) 34.0 (8.5)
LOCF (SD) 36.1 (8.5) 37.5 (13.8) 41.6 (8.2) 38.7 (9.1) 39.3 (7.6)
Mean change (SD) 4.2 (7.7) −1.3 (11.8) 3.6 (7.9) 3.4 (8.0) 5.4 (7.9)
p-value 0.011 0.893 0.029 0.010 0.009
Adherence-related attitude domain score (6 items) Baseline (SD) 8.0 (1.9) 9.1 (2.1) 9.2 (2.1) 8.4 (2.0) 8.6 (2.0)
LOCF (SD) 8.8 (2.3) 9.1 (3.0) 9.9 (2.1) 9.5 (2.2) 9.8 (1.9)
Mean change (SD) 0.8 (2.4) −0.4 (3.4) 0.8 (2.0) 1.0 (2.9) 1.2 (2.0)
p-value 0.150 0.871 0.060 0.026 0.046
Psychosocial functioning domain score (24 items) Baseline (SD) 23.6 (6.9) 30.1 (8.8) 29.2 (7.6) 26.8 (6.4) 25.4 (7.3)
LOCF (SD) 27.3 (7.5) 28.4 (11.2) 31.7 (7.3) 29.2 (7.7) 29.5 (6.7)
Mean change (SD) 3.4 (6.3) −1.1 (9.1) 2.8 (7.0) 2.3 (6.1) 4.2 (6.6)
p-value 0.015 0.898 0.048 0.020 0.006
*Patients eligible for evaluation in the analysis (N = 235) may have non-missing values at baseline and ≥1 post-baseline value at study endpoint (LOCF) for any
PETiT items; n values may not sum to 235 due to missing data.
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ziprasidone); however, significant increases in MCS scores
were noted for the patients switched from quetiapine (4.2
[11.3], p = 0.029) and aripiprazole (4.7 [10.4], p = 0.002)
(Table 6). Although not statistically significant, the in-
crease in MCS score (5.6 [10.2]) in patients switched
from ziprasidone was considered clinically significant
(i.e., a change in score of ±5).
When analyzed by discontinuation status, a statistically
significant improvement in the MCS score was observed
among patients who remained on lurasidone in the all
patients (p = 0.029) and sedating subgroups (p = 0.036)Table 4 Mean change in PETiT assessments by discontinuatio
Parameter All patients
Discontinued* Comp
(n = 37) (n =
PETiT total score Baseline (SD) 34.3 (7.6) 35.1
LOCF (SD) 33.7 (11.0) 39.1
Mean change (SD) −3.6 (12.4) 4.0 (
p-value** < 0.001
Adherence-related attitude
domain score (6 items)
Baseline (SD) 8.7 (1.7) 8.7 (
LOCF (SD) 8.0 (3.4) 9.6 (
Mean change (SD) −1.4 (3.4) 0.9 (
p-value** < 0.
Psychosocial functioning
domain score (24 items)
Baseline (SD) 25.6 (6.9) 26. 5
LOCF (SD) 25.8 (8.2) 29.5
Mean change (SD) −2.2 (9.7) 3.0 (
p-value** < 0.001
*Subjects who discontinued treatment with lurasidone due to any reason.
**Comparison of mean change between subjects who discontinued versus complet
Note: preswitch sedating medications include quetiapine and olanzapine; preswitchversus those who had discontinued treatment at the six-
week endpoint (Table 7). No difference was noted in the
PCS and MCS scores of patients switching from non-
sedating antipsychotics.
Discussion
Along with efficacy and safety, maintenance or improve-
ment of HRQoL is an important outcome of treatment
for patients with schizophrenia. This study is the first to
systematically examine the effects of switching clinically
stable patients with schizophrenia from their current
antipsychotic to lurasidone on HRQoL.n status among patients switched to lurasidone
Sedating Non-sedating
leted Discontinued* Completed Discontinued* Completed
198) (n = 18) (n = 65) (n = 19) (n = 133)
(9.0) 33.2 (6.9) 33.9 (9.0) 35.4 (8.3) 35.7 (9.0)
(8.9) 30.9 (11.5) 37.5 (9.6) 36.8 (10.0) 39.8 (8.4)
7.7) −4.5 (14.7) 3.9 (7.5) −2.6 (9.9) 4.0 (7.8)
0.008 0.004
2.1) 8.6 (1.2) 8.3 (2.2) 8.7 (2.2) 8.8 (2.1)
2.0) 7.4 (3.7) 9.1 (2.2) 8.6 (3.2) 9.8 (1.9)
2.4) −1.6 (4.2) 0.8 (2.3) −1.1 (2.6) 1.0 (2.4)
001 0.003 0.010
(7.9) 24.6 (6.5) 25.6 (7.9) 26.6 (7.2) 26.9 (7.9)
(7.8) 23.5 (8.5) 28.4 (8.4) 28.2 (7.4) 30.0 (7.5)
6.3) −2.9 (11.3) 3.0 (6.2) −1.5 (8.2) 3.1 (6.4)
0.028 0.011
ed treatment with lurasidone at 6-week endpoint.
non-sedating medications include risperidone, aripiprazole, and ziprasidone.
Table 5 Mean change in SF-12 physical and mental component summary scores among patients switched to
lurasidone
Parameter All patients Sedating Non-sedating
(N = 235)* (n = 83) (n = 152)
Physical component summary Baseline (SD) 47.1 (10.1) 47.1 (10.4) 47.1 (10.0)
LOCF (SD) 47.0 (9.8) 46.8 (9.6) 47.1 (9.9)
Mean change (SD) −0.2 (8.5) −0.3 (8.2) −0.2 (8.7)
p-value 0.414 0.513 0.556
Mental component summary Baseline (SD) 41.4 (11.4) 40.1 (11.6) 42.1 (11.2)
LOCF (SD) 45.2 (11.1) 44.2 (12.5) 45.8 (10.2)
Mean change (SD) 3.7 (11.5) 3.7 (13.3) 3.7 (10.4)
p-value < 0.001 0.079 < 0.001
*Patients eligible for evaluation in the analysis (N = 235) had non-missing values at baseline and ≥1 post-baseline value at study endpoint (LOCF) for any SF-12
items; n values may not sum to 235 due to missing data.
Note: preswitch sedating medications include quetiapine and olanzapine; preswitch non-sedating medications include risperidone, aripiprazole, and ziprasidone.
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ure of HRQoL for patients who have switched anti-
psychotic medications, where a patient’s well-being is
conceptualized as their subjective perception of their se-
verity of psychotic symptoms, medication side effects,
and level of psychosocial performance [28]. The SF-12
offers a more generic and well-recognized evaluation of
physical and mental status that permits comparison to
outcomes with other disorders. In populations such as
that included in the lurasidone switch study, where pa-
tients were clinically stable yet symptomatic at baseline,
it would be expected that switching to a new medication
might lead to only marginal improvements in terms of
these HRQoL outcomes. Therefore, the statistically sig-
nificant improvements demonstrated by the PETiT as-
sessment after only six weeks of lurasidone therapy are
notable and clinically important for patients switching
from other antipsychotics.
The majority of patients in the switch study showed
improvements from baseline to LOCF on the PETiT
total score and the domains of adherence-relatedTable 6 Mean changes in SF-12 physical and mental compone
patients switched to lurasidone
Parameter Quetiapine
(n = 62)
Physical component summary Baseline (SD) 45.8 (10.3)
LOCF (SD) 44.1 (9.6)
Mean change (SD) −1.3 (9.0)
p-value 0.046
Mental component summary Baseline (SD) 38.9 (10.9)
LOCF (SD) 44.2 (10.9)
Mean change (SD) 4.2 (11.3)
p-value 0.029
*Patients eligible for evaluation in the analysis (N = 235) may have had non-missing
any SF-12 items; n values may not sum to 235.attitude, psychosocial functioning, activity, patient per-
ception of cognition, and dysphoria. These findings indi-
cate that, in this study, patients switching to lurasidone
perceived improvements in a broad range of measures of
well-being. The finding of improved adherence-related
attitude following switch to lurasidone is of particular
importance, considering the role of patient perception
(e.g., of medication, clinical efficacy, AEs) in the trad-
itionally high rates of non-adherence and discontinu-
ation associated with antipsychotic medications [15-17]
and the potential cost and HRQoL implications of inad-
equate treatment (e.g., due to psychotic relapse,
hospitalization) [21,30]. The higher PETiT scores ob-
served among patients who completed lurasidone treat-
ment provides evidence that patient-reported HRQoL
may be associated with the likelihood of continuing
treatment.
When examined by preswitch antipsychotic, changes
in HRQoL were more variable. Patients switched from
quetiapine, risperidone, aripiprazole, and ziprasidone
showed statistically significant improvements in PETiTnt summary scores by preswitch medication* among
Olanzapine Risperidone Aripiprazole Ziprasidone
(n = 24) (n = 51) (n = 44) (n = 27)
50.1 (9.5) 48.1 (8.5) 46.9 (11.0) 48.6 (10.5)
51.0 (8.8) 50.4 (8.8) 46.0 (10.1) 47.0 (9.9)
1.3 (6.0) 2.4 (9.1) −2.1 (7.9) −0.4 (6.8)
0.077 0.124 0.190 0.427
43.8 (12.8) 43.8 (10.9) 42.2 (9.8) 39.5 (10.0)
44.3 (15.7) 46.2 (10.0) 45.1 (9.2) 44.9 (10.4)
0.0 (15.0) 2.6 (10.8) 4.7 (10.4) 5.6 (10.2)
0.834 0.298 0.002 0.129
values at baseline and ≥1 post-baseline value at study endpoint (LOCF) for
Table 7 Mean changes in SF-12 physical and mental component summary scores by discontinuation status among pa-
tients switched to lurasidone
Parameter All patients Sedating Non-sedating
Discontinued* Completed Discontinued* Completed Discontinued* Completed
(n = 37) (n = 198) (n = 18) (n = 65) (n = 19) (n = 133)
Physical component summary Baseline (SD) 46.8 (8.8) 47.2 (10.4) 48.3 (9.0) 46.8 (10.7) 45.3 (8.6) 47.3 (10.2)
LOCF (SD) 46.6 (10.2) 47.0 (9.8) 50.6 (7.2) 46.1 (9.9) 42.3 (11.6) 47.4 (9.8)
Mean change (SD) −1.1 (9.6) −0.1 (8.4) 1.5 (5.7) −0.6 (8.5) −3.9 (12.3) −0.1 (8.3)
p-value** 0.915 0.142 0.106
Mental component summary Baseline (SD) 41.7 (11.4) 41.3 (11.4) 39.9 (11.9) 40.2 (11.7) 43.3 (11.0) 41.9 (11.3)
LOCF (SD) 42.3 (12.2) 45.5 (10.9) 38.8 (14.7) 45.1 (12.0) 46.1 (7.5) 45.8 (10.4)
Mean change (SD) −1.6 (14.6) 4.3 (11.0) −3.5 (18.9) 4.9 (11.9) 0.5 (8.4) 4.0 (10.5)
p-value** 0.029 0.036 0.498
*Subjects who discontinued treatment with lurasidone due to any reason, at 6-week endpoint.
**Comparison of mean change between subjects who discontinued versus completed treatment with lurasidone at 6-week endpoint.
Note: preswitch sedating medications include quetiapine and olanzapine; preswitch non-sedating medications include risperidone, aripiprazole, and ziprasidone.
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in PETiT scores among patients switched from olanza-
pine. It is known that drugs in the atypical antipsychotic
class differ in pharmacological profiles, clinical response,
and the adverse effects experienced by patients [10,11].
Measures of HRQoL allow patients to consider both
their clinical response and adverse effects and to
emphasize the treatment effect that is of greater rele-
vance to them. In this study, the improvements in
HRQoL that were observed after switching to lurasidone
from widely-used antipsychotic agents with variable
adverse-effect profiles (quetiapine, risperidone, aripipra-
zole, and ziprasidone), and the maintenance of HRQoL
after switching from the highly efficacious antipsychotic
olanzapine, collectively suggest that lurasidone is both
effective and well tolerated.
The PETiT analysis additionally showed differences in
HRQoL depending on whether the pre-study medication
was sedating or non-sedating. Patients switching from
non-sedating medications showed statistically significant
improvements in the total, adherence-related attitude, and
psychosocial functioning scores of the PETiT scale; in con-
trast, the improvements observed in the sedating group
were not statistically significant. The difficulty in switching
patients from sedating to non-sedating atypical antipsy-
chotics is a well-known challenge in the treatment of
schizophrenia [31]. Subjective tolerability—how a patient
feels on their medication—may play a role in this chal-
lenge, potentially contributing to the greater improve-
ments on the PETiT score in patients switching from
non-sedating versus sedating antipsychotics [22,32,33].
Results published earlier from this study also revealed
differences in the time to treatment discontinuation and
all-cause discontinuation between patients switched from
sedating versus non-sedating antipsychotic agents [25]. The
authors suggested that attention should be paid to theemergence of insomnia or anxiety in persons who had re-
ceived a sedating antipsychotic immediately prior to switch-
ing to lurasidone.
Finally, the results of the more generic SF-12 assessment
also support the feasibility of switching to lurasidone from
other antipsychotics. Patients generally demonstrated little
change or improvements in the PCS and MCS scores, in-
dicating that their physical and mental health status was
maintained or improved by switching to lurasidone. Given
the clinical stability of the patient population at baseline
and the short six-week duration of follow-up, it is not
unexpected that no marked difference was observed in
physical component using a generic instrument such as
the SF-12 [34].
Overall, it is well recognized that the HRQoL of patients
with schizophrenia can be negatively impacted by the ef-
fects of atypical antipsychotic therapies [9-11]. The find-
ings of the current analysis are therefore important, as
maintenance or improvement of patient well-being follow-
ing switch to lurasidone may in turn make patients more
likely to adhere to and continue on therapy. As noted pre-
viously, improvements in adherence and continuation of
treatment may improve patient outcomes, such as reduc-
tions in relapse and re-hospitalization events [23,30].
This analysis is one of few published studies to exam-
ine changes in HRQoL, functioning, and health status
after switching between antipsychotics. While four rela-
tively recent investigations of patients switching to quetiapine
XR [35], aripiprazole [36], ziprasidone [37], or long-acting
injectable risperidone [38] reported on changes in cogni-
tive function, psychotic symptoms, and tolerability, only
one additionally described changes in quality of life using
the Subjective Well-being Under Neuroleptics Scale –
Brief Form [SWN-K] [37]. This study reported no signifi-
cant change in patient quality of life following switch to
aripiprazole [37].
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ity problems, symptom exacerbations, or increased use
of acute care services after switching patients between
antipsychotics [39-41]. However, the results of this clin-
ical trial, as reported by McEvoy and colleagues [25] and
described herein, demonstrate that switching to lurasi-
done has a low risk of treatment failure, discontinuation,
AEs, or of an adverse impact on patient well-being.
There are a few limitations of the current study. First,
being an open-label evaluation with no control group,
the outcomes were prone to greater bias than outcomes
from a randomized controlled clinical trial. Notwith-
standing this limitation, this naturalistic switch trial has
potential application for clinical practice guidance on
switching patients to lurasidone. Second, the six-week
duration of the study may not have been long enough
to fully capture changes in HRQoL and other outcomes.
However, such outcomes remain a critical source of
insight concerning numerous aspects of any disease, and
in particular, the perception of patient well-being in psy-
chiatric disorders such as schizophrenia. Analysis of the
longer-term effect of lurasidone on HRQoL, in both the
PETiT and SF-12 assessments, from the six-month ex-
tension phase of the trial is ongoing. Another limitation
was the study’s small sample size for the subgroup ana-
lyses, and interpretation of the subgroup results war-
rants caution. Finally, as noted previously by McEvoy
and colleagues [25], the lack of information on the pre-
switch sedation status of patients is a limiting factor in
terms of understanding the validity of categorizing the
preswitch agents as “sedating” or “non-sedating”. Still,
the clinical and now quality of life outcomes observed in
this study suggest that this distinction may be clinically
relevant to patients with schizophrenia. As suggested by
McEvoy’s group, stratification of the data on the basis of
agent or properties other than sedation could result in
different outcomes than those reported here.
Despite these limitations, the study results suggest that
stable yet symptomatic patients with schizophrenia may
be efficiently switched from other antipsychotics to
lurasidone, with potential improvements in psychosocial
functional, attitude related to adherence, and overall
mental health status.Conclusions
In conclusion, the results of the PETiT and SF-12 as-
sessments indicate that patients with schizophrenia who
switch to lurasidone from other antipsychotics may ex-
perience improvements in HRQoL within six weeks of
treatment. Further investigation of the effects of longer-
term lurasidone therapy on quality of life outcomes and
patient-reported perception of switching to lurasidone
is warranted.Abbreviations
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